VERTEX PHARMACEUTICALS INC / MA Advertising Expense
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Advertising Expense of $202.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AdvertisingExpense · last filed 2026-02-13
- VERTEX PHARMACEUTICALS INC / MA advertising expense for fiscal 2025 was $202.80M, a 136.64% increase from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA advertising expense for fiscal 2024 was $85.70M, a 87.12% increase from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA advertising expense for fiscal 2023 was $45.80M.
- VERTEX PHARMACEUTICALS INC / MA advertising expense for fiscal 2018 was $43.50M, a 23.58% increase from fiscal 2017.
| Period end | Advertising Expense 12 month |
|---|---|
| 2025-12-31 | $202.80M 10-K · filed 2026-02-13 |
| 2024-12-31 | $85.70M 10-K · filed 2026-02-13 |
| 2023-12-31 | $45.80M 10-K · filed 2026-02-13 |
| 2018-12-31 | $43.50M 10-K · filed 2019-02-13 |
| 2017-12-31 | $35.20M 10-K · filed 2019-02-13 |
| 2016-12-31 | $31.40M 10-K · filed 2019-02-13 |
| 2015-12-31 | $24.50M 10-K · filed 2018-02-15 |
| 2014-12-31 | $16.20M 10-K · filed 2017-02-23 |
| 2013-12-31 | $19.60M 10-K · filed 2016-02-16 |
| 2012-12-31 | $58.60M 10-K · filed 2015-02-13 |
| 2011-12-31 | $30.80M 10-K · filed 2014-02-11 |
| 2010-12-31 | $0.00 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |